Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Promissory Note into Preferred Stock

CEO Edward Pershing reports the conversion of a promissory note into Series D-1 Convertible Preferred Stock and subsequent conversion of preferred stock into common stock.

Summary

• On May 26, 2024, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported transactions involving the company's securities.
• An 8% unsecured convertible promissory note was converted into 18,876 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• These 18,876 shares of Series D-1 Convertible Preferred Stock were then converted into 188,760 shares of Common Stock.
• Following these transactions, Pershing directly owns 1,273,083 shares of Common Stock and $1,535,000 of Series D-1 Convertible Preferred Stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock conversions, with no inherent positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The conversion of preferred stock to common stock may dilute existing shareholders' equity.

Key Dates